8-K: Aptevo Therapeutics Announces At-The-Market Offering Agreement

Aptevo Therapeutics enters into an agreement with Roth Capital Partners to sell up to $2,959,952 of common stock through an at-the-market offering.

Summary

• Aptevo Therapeutics Inc. has entered into an At The Market Offering Agreement with Roth Capital Partners, LLC.
• The company may offer and sell shares of its common stock from time to time through Roth.
• The aggregate offering price of the shares will be up to $2,959,952.
• Roth will act as a sales agent and use commercially reasonable efforts to sell the shares.
• Roth's compensation will be 3.0% of the gross sales price of the shares sold.
• The company expects to report approximately $2.1 million of cash and cash equivalents as of March 31, 2025.
• This estimate is preliminary and subject to change.
• Net proceeds of approximately $1.9 million and $1.8 million were received from registered direct offerings which closed on April 4, 2025 and April 22, 2025, respectively.

Sentiment

Score: 5

Explanation: The announcement is neutral. While the company is raising capital, it also suggests a need for funds, balancing positive and negative aspects.

Positives

• The company has access to additional capital through the at-the-market offering.
• Recent registered direct offerings have provided approximately $3.7 million in net proceeds.

Negatives

• The company's cash position as of March 31, 2025, was approximately $2.1 million, which may indicate a need for additional funding.
• The at-the-market offering could dilute existing shareholders' equity.

Risks

• The company's preliminary cash balance is subject to change.
• The company may incur unanticipated expenses or generate lower than anticipated cash from operations.
• The company's stock price could be negatively impacted by the at-the-market offering.

Future Outlook

The company's future cash position will be affected by ongoing operations and any sales of shares under the at-the-market offering.

Industry Context

At-the-market offerings are a common way for biotech companies to raise capital, especially when they need flexibility in timing and pricing.

Comparison to Industry Standards

• Comparable companies in the biotech sector, such as XOMA Corporation and Catalyst Biosciences, have utilized ATM offerings to fund research and development.
• The 3.0% commission to Roth Capital Partners is within the typical range for ATM offerings in the biotech industry, which generally ranges from 2% to 4%.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company's employees and operations will benefit from the additional capital.

Next Steps

• The company will file a prospectus supplement with the SEC.
• Roth Capital Partners will attempt to sell shares of common stock on behalf of Aptevo Therapeutics.
• The company will use the proceeds from the offering for general corporate purposes.

Key Dates

Keywords

at-the-market offering, common stock, Roth Capital Partners, Aptevo Therapeutics, sales agreement, cash equivalents, registered direct offering, financing